Accelerate Diagnostics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 4/10/2025)
| Balance Sheet | Total Assets | 28,556,000.00 | ROE | – |
| Balance Sheet | Total Equity | -56,040,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -509,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -24,703,000.00 | – | – |
| Cashflow | Operating Cash Flow | -24,194,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -2.15 | Div. Yield | – |
| Income | Net Income | -50,045,000.00 | P/E | – |
| Income | Shares Outstanding | 23,302,000.00 | P/B | – |
| Income | Total Revenue | 11,698,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.acceleratediagnostics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more